תשאלו אותנו הכל
ReSynapse Therapeutics is a precision neuroscience company aiming to create fast-acting, long-lasting therapeutics that address critical unmet needs in depression and anxiety. We develop a novel class of multi-target compounds for serotonin (5-HT) receptors modulation. Our solution integrates complex mechanisms of action of the serotonergic system, with AI-driven structural biology to design compounds targeting multiple serotonin receptor subtypes optimizing therapeutic outcomes. Advances in AI computational chemistry tools enable now the designing of multi-target compounds with precision and selectivity, ensuring efficacy, safety, and scalability.
ReSynapse Therapeutics is a precision neuroscience company aiming to create fast-acting, long-lasting therapeutics that address critical unmet needs in depression and anxiety. We develop a novel class of multi-target compounds for serotonin (5-HT) receptors modulation. Our solution integrates complex mechanisms of action of the serotonergic system, with AI-driven structural biology to design compounds targeting multiple serotonin receptor subtypes optimizing therapeutic outcomes. Advances in AI computational chemistry tools enable now the designing of multi-target compounds with precision and selectivity, ensuring efficacy, safety, and scalability.
ReSynapse addresses the limitations of current antidepressants (SSRIs, SNRIs) and emerging psychedelic-derived therapies by developing multi-target 5-HT receptor modulators optimized for mood regulation by precision neuropharmacology. Current agents fail in ~40% of patients due to delayed onset, single-pathway focus, or hallucinogenic liabilities. ReSynapse’s platform combines AI-driven polypharmacology binding (balanced 5-HT subclasses engagement) with neuro downstream signaling to enhance synaptic remodeling without perceptual disruptions. Our iterative computational-experimental loop ensures CNS-penetrant PK/PD profiles and functional validation via neuroplasticity biomarkers (BDNF, dendritic spines). This approach targets treatment-resistant depression’s multifactorial etiology while mitigating attrition risks from off-target effects or inadequate brain exposure.
Dorit Cohen
Founder, Ph.D. at ReSynapse Therapeutics
קצת עליי:
מייסדת של מיזם בביוטק בפיתוח תרופות משולבי AI...
קראו עוד >>